Spending and board oversight irk some Elan investors
BOSTON (Reuters) - It's not just a slowing growth of its main product and an 80 percent stock decline in five months that has some big investors in Irish drugmaker Elan riled up.<div class="feedflare">
<img src="http://feedproxy.google.com/~f/reuters/businessNews?d=41" border="0"></img> (http://feeds.reuters.com/~f/reuters/businessNews?a=xs0KmHJM) <img src="http://feedproxy.google.com/~f/reuters/businessNews?i=PKoRSECY" border="0"></img> (http://feeds.reuters.com/~f/reuters/businessNews?a=PKoRSECY) <img src="http://feedproxy.google.com/~f/reuters/businessNews?i=ipPNKr82" border="0"></img> (http://feeds.reuters.com/~f/reuters/businessNews?a=ipPNKr82)
</div><img src="http://feedproxy.google.com/~r/reuters/businessNews/~4/v37nAytn_CE" height="1" width="1"/>
http://feeds.reuters.com/~r/reuters/businessNews/~3/v37nAytn_CE/idUSTRE4B96SH20081210